A Phase II Study of Sequential Docetaxel Followed by Doxorubicin/Cyclophosphamide as First-Line Chemotherapy For Metastatic Breast Cancer

Antón, Antonio; Hornedo, Javier; Lluch, Aña; Massutí, Bartomeu; Corral, Mónica; Colomer, Ramón

doi:10.3816/cbc.2003.n.034

Cited by 6 publications

(14 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only a few clinical studies have examined whether there may be advantages to treating with a taxane first followed by an anthracycline [43][44][45][46]. The randomized trials in metastatic disease show no difference in overall outcome or toxicity between the treatment arms.…”

Section: Discussionmentioning

confidence: 99%

Phase II Trial of Neoadjuvant Chemotherapy with Docetaxel Followed by Epirubicin in Stage II/III Breast Cancer

Ramaswamy

Povoski

Rhoades

et al. 2005

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Phase II Trial of Neoadjuvant Chemotherapy with Docetaxel Followed by Epirubicin in Stage II/III Breast Cancer

Ramaswamy

Povoski

Rhoades

et al. 2005

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…In a study of 30 patients from Spain [34], 3 cycles of docetaxel gave a 60% response rate which rose to 73% after 3 cycles of AC were added. In another study of 106 patients, docetaxel with adriamycin was used sequentially or alternatively in MBC.…”

Section: Discussionmentioning

confidence: 99%

A Clinical Phase II Study of a Non-Anthracycline Sequential Combination of Cisplatin-Vinorelbine Followed by Docetaxel as First-Line Treatment in Metastatic Breast Cancer

Shamseddine

Otrock²,

Khalifeh³

et al. 2006

Oncology

View full text Add to dashboard Cite

Background: We tested a sequential combination regimen using cisplatin and vinorelbine (PVn) followed by docetaxel as first-line chemotherapy in a phase II clinical trial in metastatic breast cancer (MBC). Patients and Methods: Thirty-five patients were enrolled. Cisplatin 80 mg/m² was given on day 1 and vinorelbine 30 mg/m² on days 1 and 8 every 3 weeks for 4 cycles. Responding patients received docetaxel 75 mg/m² every 21 days for a maximum of 4 cycles. Three patients were excluded from analysis because of death unrelated to treatment. Results: After a median follow-up of 14 months, 32 patients completed the study. The overall response rate was 53.1%. Complete remission was seen in 5 patients (15.6%), partial response in 12 (37.5%), stable disease in 6 (18.75%), and progressive disease in 9 patients (28.1%). Median time to disease progression was 8 months (range 1–24). At 24 months, 12 (37.5%) patients were alive. A total of 183 cycles were administered. Febrile neutropenia was observed in 4 patients (2.2%). Grade II nephrotoxicity occurred in 12 cycles (6.5%) and grade III vomiting in 31/183 cycles (16.9%). Discussion: PVn is a feasible non-anthracycline option as first-line chemotherapy in patients with metastatic breast cancer and has acceptable toxicity. The sequential addition of 4 cycles of docetaxel following 4 cycles of PVn did not improve the overall response rate and results.

show abstract

“…AC followed by D (or the reverse sequence) has been used in neo-adjuvant and adjuvant therapy of operable breast cancer 1-5 and in the treatment of metastatic breast cancer. 6-8…”

Section: Indication(s)mentioning

confidence: 99%

“…Acute Emesis Prophylaxis : The AC regimen is predicted to cause acute emesis in greater than 90% of patients. 13 In the trials reviewed, emesis rates (all grades) ranged from 28% to 30% 1,2,5,8 with prophylactic 5HT 3 antagonist-based antiemetic therapy. Appropriate acute emesis prophylaxis includes a serotonin antagonist, a corticosteroid and a neurokinin inhibitor.…”

Section: Supportive Carementioning

confidence: 99%

“…11 In the trials reviewed, emesis rates ranged from 1% to 3%. 1,8 For most patients, prophylactic antiemetic therapy, particularly with a serotonin antagonist, generally is not required. 12-14 If needed, one of the following regimens may be given 30 minutes prior to therapy: Dexamethasone 8 to 20 mg orally, given 30 minutes before docetaxel. Prochlorperazine 10 mg orally or IV ± diphenhydramine 25 to 50 mg orally if needed, given 30 minutes before docetaxel. Metoclopramide 0.5 to 2 mg/kg orally or IV ± diphenhydramine 25 to 50 mg orally if needed, given 30 minutes before docetaxel. Promethazine 25 to 50 mg orally, or 12.5 to 25 mg IV ± diphenhydramine 25 to 50 mg orally if needed, given 30 minutes before docetaxel. …”

Section: Supportive Carementioning

confidence: 99%

See 1 more Smart Citation

Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC Followed by D) in the Treatment of Breast Cancer

Waddell¹,

Solimando²

2006

Hosp Pharm

View full text Add to dashboard Cite

The increasing complexity of cancer chemotherapy increases the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy, and review various agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr., President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, E-mail: OncRxSvc@aol.com; or J. Aubrey Waddell, Associate Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, E-mail: waddfour@charter.net.

show abstract

A Phase II Study of Sequential Docetaxel Followed by Doxorubicin/Cyclophosphamide as First-Line Chemotherapy For Metastatic Breast Cancer

Cited by 6 publications

References 21 publications

Phase II Trial of Neoadjuvant Chemotherapy with Docetaxel Followed by Epirubicin in Stage II/III Breast Cancer

Phase II Trial of Neoadjuvant Chemotherapy with Docetaxel Followed by Epirubicin in Stage II/III Breast Cancer

A Clinical Phase II Study of a Non-Anthracycline Sequential Combination of Cisplatin-Vinorelbine Followed by Docetaxel as First-Line Treatment in Metastatic Breast Cancer

Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC Followed by D) in the Treatment of Breast Cancer

Contact Info

Product

Resources

About